• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Poster 307: Non-Rhythmic Recurrent Shaking After Right Basal Ganglia Stroke: A Case Report
Aaron Hanyu-Deutmeyer: My spouse/partner has a relationship with Allergan Speakers bureau, My spouse/partner has a relationship with Allergan provided Botox for injection
Source: PM and R - September 1, 2017 Category: Rehabilitation Authors: Aaron A. Hanyu-Deutmeyer, Padma K. Srigiriraju Source Type: research

FDA Approves Botox for Lower Limb Spasticity FDA Approves Botox for Lower Limb Spasticity
The FDA has approved a new indication for Allergan's Botox (onabotulinumtoxinA): lower limb spasticity seen after stroke and in other neurologic disorders. FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - January 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

BOTOX(R) (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients
This Positive Opinion Paves the Way for a Second Indication for BOTOX® in Adult Spasticity Associated with Stroke MARLOW, England, May 1, 2014 -- (Healthcare Sales & Marketing Network) --Today, Allergan Inc. announced that BOTOX® has received a... Biopharmaceuticals, RegulatoryAllergan, BOTOX, Adult Spasticity, limb spasticity, stroke
Source: HSMN NewsFeed - May 1, 2014 Category: Pharmaceuticals Source Type: news

Response to IncobotulinumtoxinA After Resistance to OnabotulinumtoxinA and RimabotulinumtoxinB (P7.061)
CONCLUSIONS:Switching to incobotulinumtoxinA after secondary resistance to onabotulinumtoxinA and rimabotulinumtoxinB may be a viable treatment option in dystonia.Study Supported by:National Institutes of Health- National Institutes of Neurological Diseases and Stroke and the Dystonia Medical Research FoundationDisclosure: Dr. Ramos has received personal compensation for activities with the National Inistitutes of Health as an employee, and the Dystonia Medical Research Foundation. Dr. Karp has nothing to disclose. Dr. Lungu has nothing to disclose. Dr. Alter has nothing to disclose. Dr. Hallett has received personal compe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ramos, V., Karp, B., Lungu, C., Alter, K., Hallett, M. Tags: Movement Disorders: Dystonia Treatment Source Type: research

Spinning Out of Control: The Black Box of Basilar and Hemiplegic Migraine (P7.176)
CONCLUSIONS:In this retrospective study, triptans were used effectively with no subsequent vascular events for the abortive treatment of migraines with basilar and hemiplegic features. This data also suggests that beta blockers, tricyclic anti-depressants, anti-convulsants, and Botox injections have some efficacy in the treatment of migraines with basilar type and hemiplegic features.Disclosure: Dr. Krel has nothing to disclose. Dr. Mathew has nothing to disclose. Dr. Spinner has received personal compensation for activities with Merz Pharma and Allergan Inc. as speaker bureau member. Dr. Joshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Krel, R., Mathew, P., Spinner, W., Joshi, S. Tags: Headache: Treatment Source Type: research

A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A (P3.042)
CONCLUSIONS: OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/assessments and outcomes measures.Study Sponsored by: Allergan, Inc.Disclosure: Dr. Patel has received personal compensation for activities with Allergan Inc. Dr. Manack has received personal compensation for activities with Allergan Inc.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Patel, P., Manack, A. Tags: Neural Repair and Neuro-rehabilitation: Clinical Source Type: research

OnabotulinumtoxinA in Lower Limb Spasticity: Safety Results from a Pooled Analysis (P03.266)
CONCLUSIONS: OnabotulinumtoxinA treatment in lower limb spasticity was found to be safe and well-tolerated. Majority of AEs were considered not related to onabotulinumtoxinA and treatment-related AEs are consistent with the known mechanism of action of onabotulinumtoxinA.Supported by: Allergan, Inc.Disclosure: Dr. Earl has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Earl holds stock and/or stock options in AGN and GlaxoSmithKline, Inc. Dr. James has received personal compensation for activities with Allergan, Inc as an employee. Dr. Li has received personal compensation for activit...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Earl, N., James, L., Li, H.-I., Shi, G., Demos, G., Dimitrova, R. Tags: P03 Neural Repair Source Type: research

OnabotulinumtoxinA Efficacy in Lower Limb Spasticity: Results of Three Studies (P03.264)
CONCLUSIONS: OnabotulinumtoxinA (300U) significantly decreases ankle flexor tone in adults with post-stroke lower-limb spasticity.Supported by: Allergan, Inc.Disclosure: Dr. Dimitrova has received personal compensation for activities with Allergan, Inc. as an employee. Consulting service from Glaxo-Smith-Kline, Japan.....Financial support from GSK Japan, Eisai Dr. Kaji has received personal compensatino for activities with Glaxo-Smith-Kline, Japan as a consultant. Dr. Kaji has received research support from GSK Japan, Eisai. Dr. Ward has received personal compensation for activities with Allergan Inc. as a participant on a...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Dimitrova, R., Kaji, R., Ward, A., Li, H.-I., Fulford-Smith, A., Earl, N. Tags: P03 Neural Repair Source Type: research